cyrilzakka/clinical-trials huggingface dataset:
Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?

The goal of the study is to investigate the efficacy of an evidence-based weight loss intervention, on a background of quality health care, on asthma control among obese adults. The intervention will employ a combination of recommended dietary and physical activity changes, and behavioral modification techniques.


Eligibility Criteria:
Inclusion Criteria:

Participants will meet all of the following:

* Age: 18-70 years of age;
* Obesity: BMI \>30.0 kg/m2;
* Physician-diagnosed asthma that is poorly controlled:

  * Documented diagnosis of asthma on the current medical problem list
  * Currently prescribed an anti-asthma medication
  * Overall score \<20 on the Asthma Control Test (ACT)64 or a score\<3 on any of the first four ACT questions regarding symptoms, nighttime awakening, interference with normal activity, and SABA use for symptom relief
  * Demonstrable airway reversibility
* Seen in primary care at Kaiser at least once in the preceding 24 months;
* KPNC member for \>1 year.

Exclusion Criteria:

Any of the following will exclude participants from the study:

* Inability to speak, read or understand English;
* Intermittent asthma, defined as either seasonal asthma or (daytime asthma symptoms \< 2x/week and nocturnal symptoms \< 2x/month and no use of long-term control medications);
* Diagnosis of COPD (emphysema or chronic bronchitis) on the current medical problem list or suggested by spirometry at baseline;
* Unwilling to attempt weight loss, including unwillingness to perform self-monitoring;
* Body weight change (+/-) \> 10 pounds or use of weight-loss medications in the preceding 3 months;
* Inability to perform pulmonary function tests by spirometry in a consistent manner;
* Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, diabetes, renal, liver), unstable heart disease, heart failure, and ongoing substance abuse;
* Diagnosis of psychiatric disorders that would limit adequate informed consent or ability to comply with study protocol;
* Regular use of medications that can cause weight gain (e.g., oral corticosteroids, insulin, certain oral hypoglycemics, certain antidepressants, etc.);
* Under treatment for cancer or another condition that may prevent completion of follow-up;
* Diagnosis of a terminal illness and/or in hospice care;
* Use of a pacemaker or other implanted medical devices;
* Pregnant, planning to become pregnant, or lactating;
* Actively enrolled in a care management program focused on weight loss at Kaiser or elsewhere;
* Already enrolled or planning to enroll in a research study that would limit full participation in the study or confound the observation and interpretation of the study's findings;
* Family household member already enrolled in the study;
* No longer receiving primary care from Kaiser, or planning not to do so within the study period;
* PCP determination that the study is inappropriate or unsafe for the patient;
* Investigator discretion for clinical safety or protocol adherence reasons.
Interscalene Block and Dysfunction Diaphragmatic

The study seeks to show that interscalene injection of a small volume (\<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.

It's a prospective monocentric randomized controlled clinical trial in 2 parallel groups in double blind.

the study concerns patients undergoing arthroscopic shoulder surgery with ISB. The study seeks to show that interscalene injection of a small volume (\<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.

Randomization in one of the two arms:

* Experimental group: \<8ml ropivacaine 0.1%.
* Control group: \<8mL of ropivacaine 0.5%.

Evaluation of diaphragmatic stroke by ultrasound and ventilatory function by spirometry and snip test before performing the ISB, then after installation of the ISB.

Performing the surgical procedure under general anesthesia assessment of postoperative analgesia and patient satisfaction during the following 48 hours.

Eligibility Criteria:
Inclusion Criteria:

* orthopedic surgery compatible with interscalene block
* french speaking
* Patient who signed consent to participate in the study

Exclusion Criteria:

* Pregnant woman
* ASA score \> 3
* Severe chronic respiratory insufficiency
* COPD \>3 or 4 of Gold score
* coagulation trouble
* Allergic to medication involved in the study
* Breastfeeding women
Mhealth Application for anTicoagulation Care in Atrial Fibrillation

This study will assess the benefits of using a mobile health application designed for shared decision aid in anticoagulation therapy in patients with Atrial Fibrillation (AF). The aim is to improve their treatment adherence and time in therapeutic International Normalized Ratio (INR) range. The results of this study have the potential to lead to a sustainable and resource-efficient strategy for better prevent thromboembolic events in patients with atrial fibrillation.

Atrial Fibrillation is a common disease, with important burden on morbidity and mortality and a challenging management. Its incidence and healthcare costs have increased over the decades. One of the most important features of this arrhythmia is its stroke risk, which can be reduced with the use of anticoagulants. Deciding about anticoagulation therapy is complicated due to frequent competing comorbidities and potential harms of the therapy itself. To achieve better outcomes in preventing stroke, it is paramount that decisions about atrial fibrillation treatment be shared between providers and patients.

Mobile health is empowering individuals to assume a more active role in monitoring and managing their chronic conditions and therapeutic regimens. Also, health professionals are being provided with fast and point-of-care information, which can facilitate decision-making.

Therefore, this study will investigate the effects of an mHealth application idealized to aid shared decision and improve anticoagulation care in atrial fibrillation.

Adults with atrial fibrillation will be recruited from anticoagulation outpatient clinics and Basic Health Units and randomized to either (1) an intervention group in which the mHealth application will be used during the consultations or (2) a control group receiving the usual care with anticoagulation.

It is hypothesized that the intervention group will achieve better anticoagulation outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Adults \>=18 years
* Diagnostic of atrial fibrillation
* Indication of oral anticoagulation by their physician, based on risk scores
* Ability to speak, hear and understand Portuguese
* Able to receive and read text messages through a cell phone

Exclusion Criteria:

Physical impairments that prevent completion of the intervention, cognitive impairments that jeopardize informed consent and/or intervention comprehension and not fluent in Portuguese.
HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt

An observational double-blind cohort study that examined the association between HCV viral hepatitis, blood sugar level and systolic blood pressure in the Egyptian population

a cohort study on greater than 70000 Egyptian patients had been conducted. for all patients,1- we detected the Hepatitis C Virus (HCV) RNA antigens ( hepatitis C virus)presence using BIOLINE HCV kits( qualitative test for diagnosis of hepatitis C virus in the blood), For all positive patients, confirmatory rapid screening test was performed and all patients who tested positive twice underwent a qPCR test using QIAampMinElute Virus Spin kit (Thermo Fisher Scientific, Waltham, MA, USA) performed according to the manufacturer's recommended protocol.

2- Investigators measured blood sugar levels for each patient using ACCU-CHEK kits(finger stick sugar level measurement) 3- Measured systolic blood pressure for each patient was measured using mercury meters.

4-for all patients investigators obtained full medical history regarding the presence or absence of chronic diabetes, chronic hypertension, coronary artery disease, kidney impairment with dialysis or chronic obstructive pulmonary disease.

5- for all patients investigators listed age, gender, and body mass index. 66121 patients were negative for HCV and 4852 were positive for HCV. Investigators measured the association between HCV presence, high blood sugar levels and high systolic blood pressure.

It is supposed that this is the largest study in the world that examined both associations.

In a word, this study was responding to a specific question: is hepatitis c virus presence is associated with high blood pressure or high sugar level or both or not associated???

Eligibility Criteria:
Inclusion Criteria

* Egyptian citizens from 18 years to 80 years.

Exclusion Criteria:

* Patients younger than 18 years or older than 80 years
Non-invasive Substrate Evaluation in Atrial Fibrillation

The study aims to assess the right and left atrial electrophysiological substrate in atrial fibrillation patients using the invasive electroanatomic map (basal and with extraestimulus) as well as its correlation with cardiac magnetic resonance and electrocardiographic imaging. The results will also be compared when the patient is in sinus rhythm and atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Atrial fibrillation paroxysmal or persistent with criteria for percutaneous ablation

Exclusion Criteria:

* Cardiomiopathy (FEVI\<40%) or significant valvulopathy.
* MRI not possible or contraindicated.
* Previous atrial fibrillation ablation.
Early Percutaneous Vertebroplasty Versus Standard Conservative Treatment in Thoracolumbar Vertebral Fractures

The aim of this study is to evaluate the efficacy of carrying out early vertebroplasty procedure, compared to the standard conservative treatment (corset), in order to prevent residual deformations that could occur in complications of vertebral fractures that are medically treated using a corset.

This is a monocentric, randomized, parallel group, prospective and open-label study.

In this study, 58 patients with a vertebral fracture no more than 10 days old (with a max of 15 days old) will be enrolled. Treatment will be randomly allocated in 2 groups: Early percutaneous vertebroplasty (EPV group) or standard conservative treatment (corset, CT group). Patients will be followed up during 3 months after treatment. They will receive standard care for a vertebral fracture at the Grenoble-Alpes University Hospital.

Evaluated criteria: Vertebral kyphosis evolution, Pain, Efficacy and Quality of vertebroplasty procedure, Tolerance and observance of the standard treatment, Safety, Physical performance, Quality of life, Autonomy.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 50 years
* Fracture localisation : vertebrae from T8 to L5
* Recent fracture (\< 10 days, maximum 15 days)
* CT scan showing a fracture of the superior endplate and of the anterior cortex of the vertebral body of type A1 according to the Magerl classification AND vertebral kyphosis deformation \< 30°
* Patient affiliated to the French social security system or an equivalent system
* Patient who has signed consent form

Exclusion Criteria:

* Multiple level fracture
* Repeated fracture at the same level
* Others peripheral fractures
* Contraindication for percutaneous procedure
* Contraindication for vertebroplasty procedure (pathology with risk of decompensation, coagulation problems, deformation considered by the surgeon to be inaccessible by vertebroplasty procedure, presence of an infected site)
* Contraindication for anasthesia
* Methylmethacrylate (MMA) allergy known
* Impossibility to plan the start of the treatment (set up of treatment or carrying out of a vertebroplasty gesture) within a maximum deadline of 15 days after the fracture
* Body Mass Index (BMI) \> 31,5
* Progressive local infection
* Progressive local cancer
* Patient presenting cognitive disorder with behavioural disorder which could disturb the treatment
* Non-cooperative patient
* Patient who can not be followed up at Grenoble hospital during the 3 months of the study
* Patient concerned by articles L1121-5, L1121-6, L1121-8 of the French public health code
Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study satiety in healthy individuals.

TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study, the investigators will be stimulating the brain to learn more about the role of the cerebellum in satiety.

The purpose of this study is to conduct a circuit manipulation experiment to test the hypothesis that targeting the cerebellum can alter activity in response to food cues to advance the understanding of the involvement of the cerebellar-striatal circuit in feeding behavior.

Participants will undergo an initial screening session to complete informed consent and undergo baseline assessments including physical activity and food craving. Participants will additionally undergo an MRI scan that includes structural and resting-state functional magnetic resonance imaging (rsfMRI). These rsfMRI imagines will be used to isolate individual resting state networks for targeting of rTMS modulation.

Participants will then complete two separate testing sessions involving MRI imaging and food intake assessments before and after rTMS. One visit will involve consumption of a filling meal; the other visit will be completed following an overnight fast.

Eligibility Criteria:
Inclusion Criteria:

* Healthy individuals aged 18 to 65
* BMI of 20-35.0 kg/m2
* Normal or corrected-to-normal vision
* Good general health
* Ability to understand and willingness to sign written informed consent document

Exclusion Criteria:

* Current and/or past medical conditions
* Current and/or past eating disorder
* On a restricted diet and/or taking weight loss medication(s)
* History of bariatric surgery
* Weight fluctuation \>3% in past 3 months
* Recent history of illicit recreational drug abuse
* Current nicotine use
* Intellectual disability
* Conditions that might result in increased risks of side effects or complications from TMS or MRI
Study of the Choroidal Thickness Variations After Ingestion of RedBull® Energy Drink

The choroid is a richly vascularized conjunctive tissue, providing the nutritive elements to the pigmentary epithelium and the photoreceptors of the retina. It drains 80% of the eye's blood. The choroidal thickness fluctuates according to the state of fullness of its constitutive vessels. The choroid and the neuroretina (separate by the pigmentary epithelium) are intimately linked and are subject to modifications during the ingestion of caffeine and taurine combined. Several authors have shown a significant decrease of the choroidal thickness lasting at least 4 hours after the ingestion of a small coffee. This decrease may be caused by caffeine's vasoconstrictor effect. Taurine is the most abundant amino acid in the retina. Recent studies have shown the importance of this amino acid in the physiology of both, retinal pigmentary epithelium and retinal ganglion cells.

RedBull® is an energizing drink, where one single 25 cl can contains 80 mg of caffeine (the equivalent of a coffee mug) and 1 g of taurine.

This pilot trial aims to study the variations of the choroidal thickness and to describe possible modifications within the pigmentary epithelium, due to the ingestion of caffeine and taurine. The results of this study will act as a reference for an ulterior trial aiming specific choroidal pathologies of young patients, such as the central serous chorioretinitis.


Eligibility Criteria:
Inclusion Criteria:

* Ages 18-45 years old
* subject under no medical treatment who can alter choroidal depth (sildenafil, diuretics, steroids, etc)
* Non smoker
* subject who has not ingested any caffeine within the 12 hours prior to the trial's inclusion
* subject well informed of the trial and having signed consent

Exclusion Criteria:

* subject with retinal and/or choroidal abnormalities
* Diabetic subject
* Hypermetropia \> +3 diopters and myopia \< -3 diopters
* History of intra-ocular surgery or laser
* subject with a history of retinal pathologies
* Subject not affiliated to French social security
* Subject under juridical protection
* Pregnant woman
Electro-thumbtack Needle Therapy for Chronic Neck Pain

This prospective trial will be a single-center, participant-blinded, randomized controlled trial. It is reported in previous studies that both acupuncture and transcutaneous electrical nerve stimulation are effective in reducing neck pain comparing to placebo or exercise. Taking into account the convenience of electro-thumbtack needle therapy shown in clinical practice, this study aims to evaluate the efficacy and safety of electro-thumbtack needle therapy for alleviating chronic neck pain compared with sham electro-thumbtack needle therapy.

Chronic neck pain is a commonly experienced symptom that often influences work efficiency and life satisfaction for years. A total of 180 participants suffering mechanical chronic neck pain will be recruited and randomized into either electro-thumbtack needle therapy group or sham electro-thumbtack needle therapy group. All participants will receive the standardized neck exercise instruction at their first treatment session and will be asked to perform the exercise once every day during 4-week treatment. All assessments will be performed by the assessor and the assessment results will be all kept from the acupuncturist. The statistician will be involved in neither assessment nor treatment and will be blinded regarding intervention group code.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed with neck pain with headaches or neck pain with movement coordination impairments according to the Orthopaedic Section of the American Physical Therapy Association (APTA);
2. Aaged 18-65 years;
3. History of neck pain for at least 3 months;
4. A score of ≥4 in Numerical Rating Scale for neck pain (NRS-NP) assessing the average neck pain intensity over last 7 days until the day of recruitment.

Exclusion Criteria:

1. Diagnosed with neck pain with mobility deficits or neck pain with radiating pain according to the Orthopaedic Section, APTA;
2. Known specific reason leading to neck pain such as tumor, immune disease, endocrine and metabolic disorders, neurological abnormalities, cervical vertebra fracture, cervical dislocation;
3. Acute neck pain or neck pain with radiating pain or upper limb symptoms;
4. Neck pain with sensory or motor disturbance;
5. Prior cervical spine surgery or congenital abnormalities;
6. Experiencing medical dispute litigation;
7. Have received acupuncture in last 30 days;
8. In need of analgesic, muscle relaxant, hormones, or bearing greater pain from another area;
9. Allergic to metal or adhesive tape, or carrying cardiac pacemaker, or skin damaged at selected acupoints;
10. Disable to communicate or critically ill;
11. Drug or alcohol dependent;
12. Currently or planning to be pregnant.
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis

This prospective randomized multicenter study evaluates whether the decision to prescribe antifungals guided by (1,3)-β-D-glucan in comparison to standard of care shortens time to antifungal therapy and reduces mortality in patients with severe sepsis or septic shock and a high risk of invasive candida infection.

(1,3)-β-D-glucan is a component of the cell wall of many fungi including candida spp. and is present in the blood of patients with invasive candida infection (ICI). Several studies showed a good diagnostic accuracy (1,3)-β-D-glucan in predicting ICI. However, others have challenged (1,3)-β-D-glucan as a diagnostic tool in critically ill patients as many substances used in the intensive care unit might affect the results of the assay. The goal of this study is to investigate whether (1,3)-β-D-glucan can early identify sepsis patients in need of antifungal therapy. Patients randomized to the standard of care group receive antifungals depending on microbiological results according to current guidelines. Patients randomized to the BDG group receive antifungals depending on the (1,3)-β-D-glucan plasma concentration on day 1 and day after diagnosing sepsis. Therapy may be modified according to microbiological results.

Eligibility Criteria:
Inclusion Criteria:

* Severe sepsis or septic shock
* Onset of sepsis no longer than 24 hours
* Increased risk of invasive candida infection with at least one of the following criteria:

  * total parenteral nutrition ≥48 hours
  * abdominal surgery within the last 7 days
  * antimicrobial therapy for at least 48 hours within the last 7 days
  * Acute or chronic renal failure with renal replacement therapy
* Age ≥18 years
* Informed consent of the patient or legal representative or delayed consent process is started if patient is incapable of giving informed consent and no legal representative is available.

Exclusion Criteria:

* Pregnant or lactating women
* Ongoing invasive candida infection
* systemic antifungal therapy
* liver cirrhosis Child C
* cardiopulmonary bypass within the last 4 weeks
* treatment with immunoglobulins within the last 14 days
* immunosuppression (solid organ transplantation, AISA, leukopenia)
* participation in another intervention study
* no commitment to full therapy (i.e. DNR order)
* Infauste Prognose aufgrund von Nebenerkrankungen
* kin to or colleague of study personnel
Retrospective Study of Germ Cell Tumors of the Central Nervous System

Retrospectively analyzing the epidemiological and clinical characteristics, treatment, recurrence, prognosis and prognostic factors of the germ-cell tumors of central nervous system in a single center.

Clinical data of patients with germ-cell tumors of central nervous system who were treated in the Department of Neuro-oncology, Sanbo Brain Hospital Capital Medical University between January 2007 and December 2022 were retrospectively collected, and the epidemiological and clinical characteristics, treatment, recurrence, prognosis and prognostic factors of the disease were analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Clinically or pathologically diagnosed as germ cell tumor of the central nervous system.
* Have received antitumor therapy.
* Patients who were clinically diagnosed based on neuroimaging characteristics and response to radiotherapy or chemotherapy were allowed for enrollment.

Exclusion Criteria:

* Patients with missing key information such as tumor location, surgical, chemotherapy and radiotherapy data, and post-treatment evaluation.